BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Clark IA, Vissel B. Therapeutic implications of how TNF links apolipoprotein E, phosphorylated tau, α-synuclein, amyloid-β and insulin resistance in neurodegenerative diseases. Br J Pharmacol 2018;175:3859-75. [PMID: 30097997 DOI: 10.1111/bph.14471] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Clark IA, Vissel B. Neurodegenerative disease treatments by direct TNF reduction, SB623 cells, maraviroc and irisin and MCC950, from an inflammatory perspective – a Commentary. Expert Review of Neurotherapeutics 2019;19:535-43. [DOI: 10.1080/14737175.2019.1618710] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
2 Clark IA. Background to new treatments for COVID-19, including its chronicity, through altering elements of the cytokine storm. Rev Med Virol 2021;31:1-13. [PMID: 33580566 DOI: 10.1002/rmv.2210] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
3 Clark IA. How diseases caused by parasites allowed a wider understanding of disease in general: my encounters with parasitology in Australia and elsewhere over the last 50 years. Int J Parasitol 2021:S0020-7519(21)00298-8. [PMID: 34757090 DOI: 10.1016/j.ijpara.2021.10.002] [Reference Citation Analysis]
4 Rauf A, Badoni H, Abu-Izneid T, Olatunde A, Rahman MM, Painuli S, Semwal P, Wilairatana P, Mubarak MS. Neuroinflammatory Markers: Key Indicators in the Pathology of Neurodegenerative Diseases. Molecules 2022;27:3194. [PMID: 35630670 DOI: 10.3390/molecules27103194] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
5 Jung YJ, Tweedie D, Scerba MT, Kim DS, Palmas MF, Pisanu A, Carta AR, Greig NH. Repurposing Immunomodulatory Imide Drugs (IMiDs) in Neuropsychiatric and Neurodegenerative Disorders. Front Neurosci 2021;15:656921. [PMID: 33854417 DOI: 10.3389/fnins.2021.656921] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Hölscher C. Protective properties of GLP-1 and associated peptide hormones in neurodegenerative disorders. Br J Pharmacol 2021. [PMID: 33900631 DOI: 10.1111/bph.15508] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Jankovska N, Olejar T, Matej R. Extracellular Amyloid Deposits in Alzheimer's and Creutzfeldt-Jakob Disease: Similar Behavior of Different Proteins? Int J Mol Sci 2020;22:E7. [PMID: 33374972 DOI: 10.3390/ijms22010007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
8 Wei Z, Koya J, Reznik SE. Insulin Resistance Exacerbates Alzheimer Disease via Multiple Mechanisms. Front Neurosci 2021;15:687157. [PMID: 34349617 DOI: 10.3389/fnins.2021.687157] [Reference Citation Analysis]
9 Morris GP, Clark IA, Vissel B. Questions concerning the role of amyloid-β in the definition, aetiology and diagnosis of Alzheimer's disease. Acta Neuropathol 2018;136:663-89. [PMID: 30349969 DOI: 10.1007/s00401-018-1918-8] [Cited by in Crossref: 103] [Cited by in F6Publishing: 84] [Article Influence: 25.8] [Reference Citation Analysis]
10 Hölscher C. Insulin Signaling Impairment in the Brain as a Risk Factor in Alzheimer's Disease. Front Aging Neurosci 2019;11:88. [PMID: 31068799 DOI: 10.3389/fnagi.2019.00088] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 12.3] [Reference Citation Analysis]
11 Tsai YR, Chang CF, Lai JH, Wu JC, Chen YH, Kang SJ, Hoffer BJ, Tweedie D, Luo W, Greig NH, Chiang YH, Chen KY. Pomalidomide Ameliorates H₂O₂-Induced Oxidative Stress Injury and Cell Death in Rat Primary Cortical Neuronal Cultures by Inducing Anti-Oxidative and Anti-Apoptosis Effects. Int J Mol Sci 2018;19:E3252. [PMID: 30347766 DOI: 10.3390/ijms19103252] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
12 Clark IA, Vissel B. Therapeutic implications of how TNF links apolipoprotein E, phosphorylated tau, α-synuclein, amyloid-β and insulin resistance in neurodegenerative diseases. Br J Pharmacol 2018;175:3859-75. [PMID: 30097997 DOI: 10.1111/bph.14471] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
13 Yan Z, Yang W, Wei H, Dean MN, Standaert DG, Cutter GR, Benveniste EN, Qin H. Dysregulation of the Adaptive Immune System in Patients With Early-Stage Parkinson Disease. Neurol Neuroimmunol Neuroinflamm 2021;8:e1036. [PMID: 34301818 DOI: 10.1212/NXI.0000000000001036] [Reference Citation Analysis]
14 Jung YJ, Tweedie D, Scerba MT, Greig NH. Neuroinflammation as a Factor of Neurodegenerative Disease: Thalidomide Analogs as Treatments. Front Cell Dev Biol 2019;7:313. [PMID: 31867326 DOI: 10.3389/fcell.2019.00313] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 11.0] [Reference Citation Analysis]
15 Hutten DR, Bos JHJ, de Vos S, Hak E. Targeting the Beta-2-Adrenergic Receptor and the Risk of Developing Alzheimer's Disease: A Retrospective Inception Cohort Study. J Alzheimers Dis 2022;87:1089-101. [PMID: 35466934 DOI: 10.3233/JAD-215057] [Reference Citation Analysis]
16 Łuc M, Woźniak M, Helemejko M, Rymaszewska J. Tackling Alzheimer's disease: Hypothetical synergism between anti-inflammatory and anti-diabetic agents. Life Sciences 2019;231:116483. [DOI: 10.1016/j.lfs.2019.05.039] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
17 Maciejczyk M, Żebrowska E, Nesterowicz M, Żendzian-piotrowska M, Zalewska A, Srivastava S. α-Lipoic Acid Strengthens the Antioxidant Barrier and Reduces Oxidative, Nitrosative, and Glycative Damage, as well as Inhibits Inflammation and Apoptosis in the Hypothalamus but Not in the Cerebral Cortex of Insulin-Resistant Rats. Oxidative Medicine and Cellular Longevity 2022;2022:1-21. [DOI: 10.1155/2022/7450514] [Reference Citation Analysis]
18 Ebrahimi K, Jourkesh M, Sadigh-Eteghad S, Stannard SR, Earnest CP, Ramsbottom R, Antonio J, Navin KH. Effects of Physical Activity on Brain Energy Biomarkers in Alzheimer's Diseases. Diseases 2020;8:E18. [PMID: 32521816 DOI: 10.3390/diseases8020018] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
19 Majbour NK, Aasly JO, Hustad E, Thomas MA, Vaikath NN, Elkum N, van de Berg WDJ, Tokuda T, Mollenhauer B, Berendse HW, El-Agnaf OMA. CSF total and oligomeric α-Synuclein along with TNF-α as risk biomarkers for Parkinson's disease: a study in LRRK2 mutation carriers. Transl Neurodegener 2020;9:15. [PMID: 32375873 DOI: 10.1186/s40035-020-00192-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]